Mirum Pharmaceuticals (MIRM) Expands No Cost Rare Disease Testing Beyond Cholestasis

• Mirum Pharmaceuticals (NasdaqGM:MIRM) and GeneDx expanded their no cost genetic testing collaboration to cover multiple rare conditions.
• The program now includes testing for early onset cataracts and peroxisomal biogenesis disorder, Zellweger spectrum disorders, alongside cholestasis.
• Patients gain access to expert variant interpretation and genetic counseling as part of the broader rare disease testing effort.
• This wider Mirum and GeneDx testing push, spanning cholestasis and new ultra rare targets, builds on themes our research has surfaced. Take a look at 2 warning signs (1 major) we have identified for Mirum Pharmaceuticals.

For a wider view across related opportunities in healthcare and drug development, consider exploring other stocks in the same space via 35 healthcare AI stocks.

Mirum Pharmaceuticals focuses on therapies for debilitating rare and orphan diseases, so expanding testing with GeneDx into conditions like early onset cataracts and peroxisomal biogenesis disorder, Zellweger spectrum disorders, aligns with its push to reach patients whose conditions are often detected late or not at all.

3 things going right for Mirum Pharmaceuticals that this headline doesn't cover.

Mirum Pharmaceuticals uses GeneDx to pressure test its rare-disease scale thesis

Mirum Pharmaceuticals' Narrative leans on the idea that a broader portfolio and better patient finding can support a much larger rare-disease commercial platform, while R&D and selling costs become more efficient over time. This expanded GeneDx collaboration plugs directly into that story by trying to turn unexplained symptoms into clearly labelled indications for Mirum therapies.

"Continued advances in precision medicine and genetics, including Mirum sponsored exome testing programs for unexplained cholestasis, early onset cataracts and PBD ZSD, are improving rare disease diagnosis rates and can accelerate patient identification for Mirum Pharmaceuticals products..."

See how the full story points towards a $153 fair value for Mirum Pharmaceuticals.

The expanded testing push clearly supports the catalyst that product breadth matters more, because it widens the funnel of genetically confirmed patients who might match LIVMARLI, Atebrioz or future bile-acid drugs. It also tightens the link between Mirum Pharmaceuticals and front line specialists in ways that companies like Vertex or Ipsen have used to deepen rare-disease franchises.

The pressure point is the Narrative assumption that R&D and related spend can taper toward about 10% of revenue over time while margins climb. Fully sponsored exome programs add to the cash burn for a business that already reported a US$40.77 million Q3 2026 loss and carries negative shareholder equity, so that cost-discipline pillar faces a tougher real-world test.

The same GeneDx announcement can look like smart portfolio infrastructure or like extra strain on a loss-making balance sheet, depending on which Mirum Pharmaceuticals Narrative you believe.

Add Mirum Pharmaceuticals to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com